With $80 million in funding from a list of high-profile backers, the startup is developing bifunctional antibodies that drag ...

With a new approach to creating thymus-targeted medicines for autoimmune diseases, Zag Bio has emerged from stealth with the ...

BioMarin Pharmaceutical (NASDAQ: BMRN) reported its third-quarter earnings after market close Monday, and they were good ...

The latest announcement is out from Shanghai Fudan Zhangjiang Bio Pharmaceutical Co ( ($HK:1349) ). Shanghai Fudan-Zhangjiang Bio-Pharmaceutical ...

BridgeBio Pharma Inc. (BBIO) on Wednesday reported a loss of $182.7 million in its third quarter. The Palo Alto, California-based company said it ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the Stocks to Buy with Exponential Growth Heading into 2026.

AI and accelerated computing are transforming the bio/pharmaceutical sector by addressing organizational, technological, and ...

The discussion turned to vital role of the human element despite AI’s increasing integration into recruitment. Recruiting leaders use AI to reduce administrative tasks, thereby giving them free time ...

BridgeBio rallied for a third straight day on Monday to hit a new all-time high as investors snapped up shares following the ...

BridgeBio Pharma (BBIO) is scheduled to announce Q3 earnings results on Wednesday, October 29th, after market close. The consensus EPS Estimate is -$0.78 (+9.3% ...

BioMarin Pharmaceutical said on Monday it plans to divest its gene therapy, a product once expected to be a blockbuster treatment for a type of rare bleeding disorder.

Grupo Financiero Galicia S.A. (NASDAQ: GGAL) gained 36% to $48.15. Shares of Argentine stocks traded higher after President ...